Chemokines and chemokine receptors in autoimmune encephalomyelitis as a model for central nervous system inflammatory disease regulation
- PMID: 14977561
- DOI: 10.2741/1284
Chemokines and chemokine receptors in autoimmune encephalomyelitis as a model for central nervous system inflammatory disease regulation
Abstract
This article focuses on the distinct role of chemokines and chemokine receptors during CNS inflammation in experimental autoimmune encephalomyelitis (EAE) as an animal model for multiple sclerosis (MS). We review the evidence that chemokines and chemokine receptors have an intrinsic role in regulating and amplifying the inflammatory reactions in EAE or MS leading to disease outcome. A variety of studies examining temporal chemokine expression patterns, using chemokine and chemokine receptor knockout mice as well as administering passive anti-chemokine antibodies indicates that these molecules are critical regulatory components for leukocyte recruitment and/or leukocyte retention in the CNS. Therefore, chemokine and chemokine receptor expression is tightly interrelated to composition of inflammatory cells in CNS lesions and the onset of clinical diseases and provide viable targets for therapeutic intervention.
Similar articles
-
Role of chemokines and their receptors in the pathogenesis of multiple sclerosis.Front Biosci. 2004 Jan 1;9:457-63. doi: 10.2741/1238. Front Biosci. 2004. PMID: 14766382 Review.
-
Upregulation of monocyte chemotactic protein-1 and CC chemokine receptor 2 in the central nervous system is closely associated with relapse of autoimmune encephalomyelitis in Lewis rats.J Neuroimmunol. 2002 Jul;128(1-2):49-57. doi: 10.1016/s0165-5728(02)00147-9. J Neuroimmunol. 2002. PMID: 12098510
-
Chemokine regulation of experimental autoimmune encephalomyelitis: temporal and spatial expression patterns govern disease pathogenesis.J Immunol. 1998 Sep 15;161(6):2667-71. J Immunol. 1998. PMID: 9743321 Review.
-
Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES.J Neuroimmunol. 2002 Jul;128(1-2):16-22. doi: 10.1016/s0165-5728(02)00121-2. J Neuroimmunol. 2002. PMID: 12098506
-
Effects of cytokine deficiency on chemokine expression in CNS of mice with EAE.J Neurosci Res. 2002 Mar 1;67(5):680-8. doi: 10.1002/jnr.10156. J Neurosci Res. 2002. PMID: 11891780
Cited by
-
GRO-α/CXCR2 system and ADAM17 correlated expression in Sjögren's syndrome.Inflammation. 2013 Jun;36(3):759-66. doi: 10.1007/s10753-013-9602-6. Inflammation. 2013. PMID: 23389772
-
Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease.J Virol. 2009 Jan;83(2):522-39. doi: 10.1128/JVI.01210-08. Epub 2008 Nov 5. J Virol. 2009. PMID: 18987138 Free PMC article.
-
Donor variability may mask dimethyl fumarate's effects on nuclear factor E2-related factor 2 in human peripheral blood mononuclear cells.BMC Res Notes. 2017 Nov 2;10(1):553. doi: 10.1186/s13104-017-2862-8. BMC Res Notes. 2017. PMID: 29096692 Free PMC article.
-
Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype.Lab Invest. 2009 Jul;89(7):742-59. doi: 10.1038/labinvest.2009.32. Epub 2009 Apr 27. Lab Invest. 2009. PMID: 19398961 Free PMC article.
-
Impaired olfactory performance and anxiety-like behavior in a rat model of multiple sclerosis are associated with enhanced adenosine signaling in the olfactory bulb via A1R, A2BR, and A3R.Front Cell Neurosci. 2024 Jul 30;18:1407975. doi: 10.3389/fncel.2024.1407975. eCollection 2024. Front Cell Neurosci. 2024. PMID: 39139401 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources